Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

Abstract: The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.

Abstract: The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. The present invention provides a crystal and a salt of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide in a crystal form.

Abstract: The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. The present invention provides a crystal and a salt of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide in a crystal form.

Abstract: According to one aspect, a microarray for nucleic acid detection includes a substrate, a negative control probe group immobilized on a first region of the substrate and provided with a plurality of first probes having different sequences, and a second probe immobilized on a second region of the substrate and containing a sequence complementary to a target nucleic acid.

Abstract: Provided is a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, includes a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.

Abstract: Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.

Abstract: Provided is a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, includes a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.

Abstract: In a nucleic acid detecting cassette in which a heating treatment chamber and a liquid delivery channel are constituted of a stationary member and flexible members, the heating treatment chamber is held by convex heating sections from both sides, whereby the heat treatment chamber and the liquid delivery channel are spatially separated from each other. Thus, it is possible to automatically execute a consistent process including nucleic acid amplification and other required treatments of the object sample as well as detection of a target nucleic acid.

Abstract: This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 ? and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain, as the active ingredient, cyclic amine derivatives represented by the following formula (I), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C1-C6 alkyl addition salts thereof.

Abstract: The present invention provides a method of preparing a detection target structure useful for detecting a target nucleotide sequence. For example, provided is a method of preparing a detection target structure from a target nucleic acid (1). The target nucleic acid includes a target nucleotide sequence 2 in a part. According to the method of the present invention, a nucleic acid is elongated by using a primer so as to permit the target nucleic acid to have a double strand structure in the portion other than the target nucleotide sequence 2, thereby affording a detection target structure 4. The present invention also provides the detection target structure thus prepared a detection method of the target nucleotide sequence by using the detection target structure, a kit for preparing the detection target structure, and an assay kit for detecting the target nucleotide sequence.

Abstract: A condensed thiophene compound of the formula (I) wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof and hydrates thereof. The compound of the formula (I) of the present invention is useful as a novel antipsychotic agent which is effective for both positive symptoms and negative symptoms of schizophrenia, which is associated with less side effects such as extrapyramidal motor disorder and the like and which is less associated with serious side effects such as agranulocytosis and the like. In addition, this compound is also useful as a therapeutic agent of Alzheimer's disease and manic-depressive illness.

Abstract: A condensed thiophene compound of the formula (I) 1

Abstract: A condensed thiophene compound of the formula (I) wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof and hydrates thereof. The compound of the formula (I) of the present invention is useful as a novel antipsychotic agent which is effective for both positive symptoms and negative symptoms of schizophrenia, which is associated with less side effects such as extrapyramidal motor disorder and the like and which is less associated with serious side effects such as agranulocytosis and the like. In addition, this compound is also useful as a therapeutic agent of Alzheimer's disease and manic-depressive illness.

Abstract: A parting layer 12, colored layer 13, reflective layer 14, and photosensitive resin layer 15 are laminated to base film 11 of relief pattern transfer sheet 10. When forming letters on the face of a timepiece, photosensitive resin layer 15 is first exposed through negative film 16. Mask areas 161 of a pattern corresponding to the letters are formed in negative film 16. Therefore, when photosensitive resin layer 15 is developed by a water wash, molded resin layer 150 of the specified pattern is left on base film 11 with parting layer 12, colored layer 13, and reflective layer 14. Pressure-sensitive adhesive layer 17 is then formed only on the surface of molded resin layer 150, and relief pattern transfer sheet 10 is bonded to the timepiece face. When relief pattern transfer sheet 10 is thereafter pulled off of the timepiece face, reflective layer 14 and colored layer 13 corresponding to the areas in which molded resin layer 150 is formed are also transferred to the timepiece face.